Study Purpose:
Use of noninvasive ventilation (NIV, also known colloquially as "Bipap") has been associated in some studies with improvement in pulmonary function, quality of life and survival. NIV is typically applied during sleep, and without the benefit of sleep study to determine the optimal settings. The investigators have shown that when NIV is used in this fashion, failure of nocturnal oxygenation and ventilation is prominent. This study is randomizing patients to standard application of NIV vs application guided by use of sleep study data to determine the effect of titrated therapy on pulmonary function, quality of life and survival.Study Status:
Not recruiting
Disease:
Amyotrophic Lateral Sclerosis (ALS)
Study Type:
Interventional
Type of Intervention:
N/A
Intervention Name:
Sleep study-guided adjustment of NIV, Standard initiation of NIV
Placebo:
Phase:
N/A
Study Chair(s)/Principal Investigator(s):
Robert C Basner, MD, Columbia University
Clinicaltrials.gov ID:
Neals Affiliated?
No
Coordinating Center Contact Information
Columbia University Medical Center
New York, New York, 10032 United States
Full Study Summary:
Use of noninvasive ventilation (NIV, also known colloquially as "Bipap") has been associated in some studies with improvement in pulmonary function, quality of life and survival. NIV is typically applied during sleep, and without the benefit of sleep study to determine the optimal settings. The investigators have shown that when NIV is used in this fashion, failure of nocturnal oxygenation and ventilation is prominent. This study is randomizing patients to standard application of NIV vs application guided by use of sleep study data to determine the effect of titrated therapy on pulmonary function, quality of life and survival.
Study Sponsor:
Columbia University
Estimated Enrollment:
25
Estimated Study Start Date:
01 / 31 / 2008
Estimated Study Completion Date:
07 / 01 / 2010
Posting Last Modified Date:
11 / 13 / 2020
Date Study Added to neals.org:
06 / 02 / 2011
Minimum Age:
18 Years
Maximum Age:
80 Years
Inclusion Criteria:- Diagnosis of probable or definite Amyotrophic Lateral Sclerosis (ALS) per El Escorial criteria
- Between ages of 18 and 80 yrs old
Exclusion Criteria:
- Inability to clear secretions from the airway
- Life expectancy < 6 months from a comorbid condition
- Dementia sufficient to impair ability to use NIV, perform respiratory muscle pressure testing (PFTs), or complete Health-related Quality of Life (HRQOL) instruments
- Inability to follow up at the ALS Center on a regular basis
- Previously diagnosed obstructive Sleep Apnea
Columbia University Medical Center
New York, New York
10032
United States